Clinical Trial

Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the immunogenicity, safety and immune persistence of recombinant trivalent rotavirus subunit vaccine in healthy infants aged 6-12 weeks and healthy toddlers aged 7-71 months.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-11-14; most recent amendment 2024-11-18.
Status change: Recruiting → Active, Not Recruiting 2023-05-22
Status change: Not Yet Recruiting → Recruiting 2023-01-31
Trial Details
NCT Number NCT05621655
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions Rotavirus Infections, Rotavirus Gastroenteritis
Enrollment 1,512 participants
Start Date 2023-01-08
Primary Completion 2023-04-29 (estimated)
Study Completion 2024-12 (estimated)
Updated on ClinicalTrials.gov 2024-11-20